مركز الكويت لمكافحة السرطان

Kuwait Cancer Control Center

(CYCLOPHOSPHamide / ADRIAmycin / Platinol)



Name: Nationality: Gender/Age:	File #: Civil ID: DOB:	Ht (cm): Wt (Kg): BSA (m²):			
Indication(s): Thymic tumors. Central line: ☐ Available ☐ NA	Allergies: ☐ NKA ☐ Yes, spe	cify;			
Parameters: Initiate treatment only if ANC ≥ 1500; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min. Baseline ECHO and/or MUGA scan before initiation of anthracycline-containing regimen. Date of pre-treatment ECHO and/or MUGA scan is LVEF is %.					
Pre-treatment Medications: (30-60 min before starting treatment) Akynzeo 1 Capsule PO (300 mg NETUpitant/0.5 mg PALONOsetron) on Day 1 Dexamethasone 10 mg PO/IV					

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS		
CYCLOPHOSPHamide	500 mg/m²	IV in 250 mL NS over 30 min.	D1		
DOXOrubicin	50 mg/m²	IV in 100 mL NS over 30 min.	D1		
CISplatin	50 mg/m²	IV in 1000 mL NS over 2 hrs.	D1		
To be repeated every 3 weeks for 6 cycles.					

Special instructions: The maximum cumulative dose of DOXOrubicin is 450 mg/m² (in normal cardiac

function) and 350 mg/m² (in case of cardiac dysfunction or exposed to mediastinal IR.

Treatment Description:

Cycle	Date	CYC	DOXOrubicin	CISplatin	Physician	Consultant
C#						
C#						
C#						
C#						
C#						
C#						
Important Notes:						

#							
#							
portant Notes: Reported grade 3/4 toxicities: □ None □ Hematological □ Non-Hematological							
If yes;	Did it indica	te hospitalization?		☐ Yes	□ No		
	Did it indica	ite chemo-delay fo	or ≥ 7 days?	☐ Yes	□ No		
	Did it indica	te dose reduction	?	☐ Yes	□ No		
	Did it indica	te G-CSF support	?	☐ Yes	□ No		
TI-CANCER TREATMENT PREPRINTED ORDER, V2 Approved: 01/Feb/2017 Printed:					Printed: 13/May/2020		